Oncology Institute director granted 31,124 RSUs

STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 31,124 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-27. Each RSU entitles him to receive one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, contingent on his continued service through that date. Following this award, Stolper directly holds 56,957 shares of common stock. The RSUs were granted at a stated price of $0.00 per share, reflecting their nature as a compensation grant rather than a market purchase.

Insider Trade Summary

Grant/Award: 31,124 shares

Grant/Award 1 txn

Insider STOLPER MARK

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	31,124	$0.00	$0.00

Holdings After Transaction: Common Stock — 56,957 shares (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Key Figures

RSUs granted: 31,124 shares Shares held after transaction: 56,957 shares Grant price per RSU: $0.00 per share +1 more

4 metrics

RSUs granted 31,124 shares Restricted stock units granted to director on 2026-07-27

Shares held after transaction 56,957 shares Director’s direct common stock holdings following the RSU grant

Grant price per RSU $0.00 per share Stated price for the compensation grant of RSUs

Vesting event 2027 annual meeting of stockholders RSUs vest in full on the date of the 2027 annual meeting, subject to continued service

Key Terms

restricted stock units (RSUs), vest in full, settlement, annual meeting of stockholders

4 terms

restricted stock units (RSUs) financial

"Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vest in full financial

"The RSUs vest in full on the date of the Issuer's 2027 annual meeting"

settlement financial

"each of which entitle the Reporting Person to receive one share ... upon settlement"

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

annual meeting of stockholders regulatory

"on the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Oncology Institute, Inc. (TOI) director Mark Stolper report in this Form 4?

Mark Stolper reported a grant of 31,124 restricted stock units of Oncology Institute, Inc. common stock. These RSUs are a form of equity compensation that convert into shares upon settlement rather than a market purchase of stock.

When do the new RSUs for Oncology Institute (TOI) director Mark Stolper vest?

The 31,124 RSUs vest in full on the date of Oncology Institute’s 2027 annual meeting of stockholders. Vesting is conditioned on Stolper’s continued service with the company through that meeting date.

How many Oncology Institute (TOI) shares does Mark Stolper hold after this RSU grant?

After the reported transaction, Mark Stolper directly holds 56,957 shares of Oncology Institute common stock. This figure includes the effect of the 31,124-share RSU award reported in the Form 4 filing.

Was cash paid for the RSUs granted to Oncology Institute (TOI) director Mark Stolper?

No cash was paid; the RSUs were granted at a stated price of $0.00 per share. This reflects a compensation award rather than a purchase of Oncology Institute common stock in the open market.

What does each RSU reported by Oncology Institute (TOI) for Mark Stolper represent?

Each RSU entitles the reporting person to receive one share of Oncology Institute common stock upon settlement. The units are subject to vesting conditions tied to continued service and the company’s 2027 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 06:52 PM Accepted by SEC EDGAR 07/29/2026 - 06:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STOLPER MARK

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A(1)		31,124	A	$0.00	56,957	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Mark Stolper	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)